David Kaplan
Dermatology · Overland Park, KSNPI 1982661849
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $306,967 of the $488,873 with a category attached, or 62.8%. 40 manufacturers reported payments, led by Bristol Myers Squibb at 24.4% of the total. Reporting peaked in 2019 at $255,787 and has fallen 94.7% since, to $13,608 in 2025. Among dermatology clinicians in KS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,929 payments — averaging $253.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bristol Myers Squibb$119K
- Pfizer$78K
- Amgen$74K
- VYNE Pharmaceuticals Inc.$39K
- Dermira, Inc.$38K
- Sanofi$35K
- plus $106K from 34 others
Across 14 payments — averaging $1970.02 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$27K
- Bristol Myers Squibb$536
What the payments were for
- Consulting fees$97,14620%
- Speaking & faculty fees$306,96763%
- Travel & lodging$44,8439%
- Food & beverage$39,3838%
- Education$5360%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$488,873 in reported general payments places this provider in the 95th percentile of 82 dermatology providers in Kansas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TremfyaGuselkumab | 12 | $238,574 |
| OtezlaApremilast | 33 | $170,450 |
| AdbryTralokinumab-Ldrm | 27 | $134,536 |
| Dupixent PenDupilumab | 17 | $68,244 |
| Pimecrolimus | 29 | $6,947 |
| Tacrolimus | 30 | $3,880 |
| Fluorouracil | 52 | $3,461 |
| Erythromycin-Benzoyl PeroxideErythromycin/Benzoyl Peroxide | 11 | $2,835 |
| Clindamycin Phosphate | 27 | $1,688 |
| Imiquimod | 82 | $1,686 |
| Finasteride | 173 | $1,581 |
| Azelaic Acid | 12 | $1,531 |
| Fluconazole | 40 | $1,494 |
| Doxycycline Hyclate | 68 | $1,341 |
| Desonide | 15 | $1,229 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonTremfya | $1,139 | $238,57412 claims |
| AmgenOtezla | $74,396 | $170,45033 claims |
| LEO Pharma Inc.Adbry | $6,729 | $134,53627 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 82 dermatology providers in Kansas.
Other dermatology in Overland Park
- Meena SinghOverland Park$181K
- Reba SuriOverland Park$7K
- Lauren Kyle TkachukOverland Park$6K
- Megan LentOverland Park$5K
- Mark McCuneOverland Park$5K
- Jeffery GravesOverland Park$3K
- Carol FouldsOverland Park$3K
- Stephen MatlockOverland Park$3K
- Mitchell GibbonsOverland Park$2K
- Lisa MorrisOverland Park$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.